Sugi Predict

Sugi Predict / Compounds / SCHEMBL20745930

SCHEMBL20745930

SCHEMBL20745930

OCc1cc(Cl)n(C(c2ccccc2)(c2ccccc2)c2ccccc2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 1/20 0.36
▸ PTGS2 P35354 2/20 0.35
▸ NOTUM Q6P988 5/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ CA2 P00918 4/20 0.32
▸ CA1 P00915 3/20 0.32
▸ CA9 Q16790 3/20 0.32
▸ GRN P28799 2/20 0.32
▸ SORT1 Q99523 2/20 0.32
▸ KCNN4 O15554 2/20 0.32
▸ KCNA3 P22001 2/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ SLC22A1 O15245 1/20 0.31
▸ NR1I2 O75469 1/20 0.31
▸ GMNN O75496 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ TRPM2 O94759 1/20 0.31
▸ ABCB11 O95342 1/20 0.31
▸ EGFR P00533 1/20 0.31
▸ LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3148117 0.82 P2RX7 (0.37) P2RX7PTGS2NOTUML3MBTL1CA2
SCHEMBL5366279 0.77 KDM4E (0.34) P2RX7PTGS2NOTUML3MBTL1CA2
SCHEMBL20745653 0.77 KMT2A (0.45) L3MBTL1MEN1LMNACYP1A2MAPT
SCHEMBL20746056 0.75 SLC16A3 (0.34) PTGS2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL27604945 0.75 KCNN4 (0.34) PTGS2L3MBTL1CA2KCNN4KCNA3
SCHEMBL20361623 0.75 KCNN4 (0.34) PTGS2L3MBTL1CA2KCNN4KCNA3
SCHEMBL5357402 0.69 P2RX7 (0.40) P2RX7PTGS2NOTUML3MBTL1CA2
SCHEMBL20746109 0.69 GAA (0.46) LMNATP53CYP1A2ADORA3MAPT
SCHEMBL27604869 0.68 NFE2L2 (0.45) L3MBTL1MEN1LMNATP53MAPT
SCHEMBL16830006 0.67 MAPK1 (0.31) MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11957680-B2 Pyruvate kinase activators for use in treating blood disorders AGIOS PHARMACEUTICALS, INC. (US) 2024-04-16 — — US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 — — US disclosed
EP-3668881-B1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS INC (US) 2023-10-04 — — EP disclosed
CN-111032046-B Pyruvate kinase modulators and uses thereof 安吉奥斯医药品有限公司 2023-09-26 — — CN disclosed
EP-3668512-B1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS INC (US) 2023-02-15 — — EP disclosed
US-20220395503-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2022-12-15 — — US disclosed
US-11464775-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2022-10-11 — — US disclosed
US-20220233541-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS, INC. 2022-07-28 — — US disclosed
US-11364240-B2 Pyruvate kinase activators for use in treating blood disorders AGIOS PHARMACEUTICALS, INC. (US) 2022-06-21 — — US disclosed
US-20210130371-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2021-05-06 — — US disclosed
US-20200206225-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS, INC. (US) 2020-07-02 — — US disclosed
EP-3668512-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF Agios Pharmaceuticals, Inc. (US) 2020-06-24 — — EP disclosed
EP-3668881-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS Agios Pharmaceuticals, Inc. (US) 2020-06-24 — — EP disclosed
CN-111032046-A Pyruvate kinase modulators and uses thereof 安吉奥斯医药品有限公司 2020-04-17 — — CN disclosed
WO-2019035865-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS INC. (US) 2019-02-21 — — WO disclosed
WO-2019035863-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. (US) 2019-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11872225-B2 Pyruvate kinase modulators and use thereof PDK1, PDK2, PDK4 P2RX7 2065/4885PTGS2 1871/4885NOTUM 3952/4885
US-11364240-B2 Pyruvate kinase activators for use in treating blood disorders PDK1, PDK2, PDK3 P2RX7 1194/4885PTGS2 1508/4885NOTUM 3861/4885
US-20210130371-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PDK1, PDK2, PDK3 P2RX7 1194/4885PTGS2 1508/4885NOTUM 3861/4885
US-20200206225-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF PDK1, PDK2, PDK4 P2RX7 2065/4885PTGS2 1871/4885NOTUM 3952/4885
US-20220233541-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF PDK1, PDK2, PDK4 P2RX7 2065/4885PTGS2 1871/4885NOTUM 3952/4885
US-20220395503-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PDK1, PDK2, PDK3 P2RX7 1194/4885PTGS2 1508/4885NOTUM 3861/4885
US-11464775-B2 Pyruvate kinase modulators and use thereof PDK1, PDK2, PDK4 P2RX7 2065/4885PTGS2 1871/4885NOTUM 3952/4885
US-11957680-B2 Pyruvate kinase activators for use in treating blood disorders PDK1, PDK2, PDK3 P2RX7 1194/4885PTGS2 1508/4885NOTUM 3861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.